Literature DB >> 33425348

Statin eligibility based on the ACC/AHA guidelines among Middle Eastern patients with diabetes mellitus presenting with acute myocardial infarction.

Mohamad I Jarrah1, Muhannad J Ababneh1, Loai Issa Tawalbeh2, Ayman J Hammoudeh3, Hanan M Barukba1, Ahmad Othman1.   

Abstract

BACKGROUND: Statin eligibility based on the American College of Cardiology/American Heart Association cholesterol guidelines among patients with diabetes admitted with first time acute myocardial infarction has not been evaluated in the Middle East.
PURPOSE: To assess statin eligibility for diabetic patients admitted with first time myocardial infarction in Jordan according to ACC/AHA guidelines.
METHODS: Consecutive patients admitted with a first acute myocardial infarction who were not taking statins, and had their serum lipoproteins measured upon hospital admission were enrolled in the study. Statin eligibility among patients with diabetes admitted with first time myocardial infarction was determined based on the ACC/AHA guidelines.
RESULTS: Of 774 patients enrolled, 292 (37.30%) had diabetes. Compared with non-diabetic patients, those with diabetes were females, older, more hypertension, more hypercholesterolemia, more triglycerides, more diastolic blood pressure, less smokers and less low density lipoprotein. Among patients with diabetes, 242 diabetic patients (82.9%) were statin eligible, including 20 (6.90%) for having high serum levels of low density lipoprotein cholesterol (LDL-C) >190 mg/dL, and 222 (76%) for being aged 40-75 years with LDL-C 70-189 mg/dL. No patient had a calculated atherosclerotic cardiovascular risk score ≥7.5%. On the other hand, 393 non-diabetic patients (81.3%) were statin eligible, including 41 (8.50%) for having high serum levels of low density lipoprotein cholesterol (LDL-C) >190 mg/dL, and 351 (72.80%) for being aged 40-75 years with LDL-C 70-189 mg/dL.
CONCLUSIONS: Based on the ACC/AHA guidelines, the majority of patients with diabetes admitted with first acute myocardial infarction would have been eligible for statin treatment if they have LDL-c >190 mg/dl or aged 40-75 years old and they have their LDL 70-189 mg/gl. More efforts should be taken for patients who are female, older than 50 years, hypertensive, elevated diastolic blood pressure have hypercholesterolemia, and elevated triglycerides because of their significant association with diabetes.
© 2020 The Authors.

Entities:  

Keywords:  ACC/AHA; Diabetes mellitus; Middle east; Statin eligibility

Year:  2020        PMID: 33425348      PMCID: PMC7782195          DOI: 10.1016/j.amsu.2020.12.036

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  28 in total

1.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

2.  STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery.

Authors:  Riaz Agha; Ali Abdall-Razak; Eleanor Crossley; Naeem Dowlut; Christos Iosifidis; Ginimol Mathew
Journal:  Int J Surg       Date:  2019-11-06       Impact factor: 6.071

3.  Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

Authors:  Kausik K Ray; Harold E Bays; Alberico L Catapano; Narendra D Lalwani; LeAnne T Bloedon; Lulu R Sterling; Paula L Robinson; Christie M Ballantyne
Journal:  N Engl J Med       Date:  2019-03-14       Impact factor: 91.245

Review 4.  Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines.

Authors:  Nivee P Amin; Seth S Martin; Michael J Blaha; Khurram Nasir; Roger S Blumenthal; Erin D Michos
Journal:  J Am Coll Cardiol       Date:  2014-05-07       Impact factor: 24.094

5.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

Review 6.  Cholesterol-Lowering Agents.

Authors:  Savvas Hadjiphilippou; Kausik K Ray
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

7.  High prevalence of diabetes and intermediate hyperglycemia - The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).

Authors:  Maria Inês Schmidt; Juliana F Hoffmann; Maria de Fátima Sander Diniz; Paulo A Lotufo; Rosane Härter Griep; Isabela M Bensenor; José G Mill; Sandhi Maria Barreto; Estela M L Aquino; Bruce B Duncan
Journal:  Diabetol Metab Syndr       Date:  2014-11-18       Impact factor: 3.320

8.  Comparing Guidelines for Statin Treatment in Canada and the United States.

Authors:  Deirdre A Hennessy; Tracey Bushnik; Douglas G Manuel; Todd J Anderson
Journal:  J Am Heart Assoc       Date:  2015-07-14       Impact factor: 5.501

9.  Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study.

Authors:  Omar Hamoui; Mohamed I Omar; Frederick J Raal; Wafa Rashed; Abdoul Kane; Mohamed Alami; Paula Abreu; Walid Mashhoud; Alawi A Alsheikh-Ali
Journal:  BMC Cardiovasc Disord       Date:  2019-03-15       Impact factor: 2.298

10.  2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.

Authors:  Brent M Egan; Jiexiang Li; Kellee White; Douglas O Fleming; Kenneth Connell; German T Hernandez; Daniel W Jones; Keith C Ferdinand; Angelo Sinopoli
Journal:  J Am Heart Assoc       Date:  2016-08-19       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.